Skip to main content

Table 2 Total CVD event rates (%, 95% CI) by presence of metabolic syndrome with different definitions in patients assigned to placebo in the FIELD study

From: Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial

  ATPIII IDF Harmonized Who
Group No MS MS Diff (95% CI) No MS MS Diff (95% CI) No MS MS Diff (95% CI) No MS MS Diff (95% CI)
Age ≥ 65 12 19 7 (3-11)‡ 15 18 3 (-2-7) 11 18 7 (2-12)† 8 19 11 (8-14)‡
Age < 65 11 12 0 (-3-3) 13 11 -2 (-5-2) 11 12 0 (-3-4) 7 12 5 (3-8) ‡
Male 12 18 6 (3-9)‡ 16 17 1 (-2-5) 12 17 5 (2-9)† 9 18 9 (6-12) ‡
Female 9 10 1 (-4-5) 7 10 2 (-2-7) 7 10 2 (-3-8) 5 11 5 (2-8) ‡
Prior CVD 22 26 3 (-4-10) 26 25 -1 (-9-6) 19 26 7 (-2-16) 18 26 8 (0-15)*
No prior CVD 9 11 2 (-0-5) 11 11 -0 (-3-3) 10 11 1 (-2-4) 6 12 6 (4-8) ‡
All patients 11 14 3 (1-5)* 14 14 -0 (-3-3) 11 14 3 (0-6)* 8 15 8 (5-10) ‡
  1. *P < 0.05, †P < 0.01, ‡P < 0.001 for the absolute risk difference for metabolic syndrome compared with no metabolic syndrome. The larger the difference, the greater the risk discrimination provided by the definition.
  2. CVD, cardiovascular disease; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; MS, metabolic syndrome; ATPIII, Adult Treatment Panel III; IDF, International Diabetes Federation; WHO, World Health Organization;